Drug Trial Radar · NCT06789861
A First in Human Study of TT5 in Single and Multiple Ascending Doses in Healthy Volunteers and Surgical Patients
Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
94
Planned (sponsor's estimate)
Start
May 23, 2025
Primary completion
Oct 1, 2026
Study completion Nov 10, 2026
Sponsor
- Lead sponsor
- Tafalgie TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a First in Human, three-parts, double-blind, randomized, placebo-controlled, single and multiple ascending dose study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TT5 at different doses in healthy and surgical participants.
Conditions
- Pain
Interventions
TT5Drug
Direct Intravenous administration of TT5 (5 ascending doses in Single Ascending Dose Part and 3 ascending doses administered during 7 days in Multiple Ascending Dose Part in healthy volunteers) Direct Intravenous administration of TT5 in surgical patients (4 doses administered on the same day) in surgical patients
Placebo - TT5 vehicleDrug
Intravenous administration of vehicule, according to the same drug regimen than TT5
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs) and serious adverse events (SAEs)Time frame: SAD cohorts: Day-1 through Day 8; MAD cohorts: Day-1 through Day 14
- Clinically significant changes in physical examinationsTime frame: SAD cohorts: Baseline through Day 8; MAD cohorts: Baseline through Day 14
- Clinically significant changes in vital signsTime frame: SAD cohorts: Day-1 through Day 8; MAD cohorts: Day-1 through Day 14
- Clinically significant changes in laboratory analysisTime frame: SAD cohorts: Day-1 through Day 8; MAD cohorts: Day-1 through Day 14
- Bond and Lader Visual Analog Scale (VAS)Time frame: SAD cohorts: Day 1 through Day 8; MAD cohorts: Day 1 through Day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cmax & PARC
Adelaide, South Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.